血液科

Kaur MN, Arnold DM, Heddle NM, Cook RJ, Hsia C, Blostein M, Jamula E, Sholzberg M, Lin Y, Kassis J, Larratt L, Tinmouth A, Carruthers J, Li N, Liu Y, Xie F

來源‎: Blood Adv. 2022;6(3):785-92.

檢索‎: PubMed 34781363

DOI碼‎: 10.1182/bloodadvances.2021005627

https://pubmed.ncbi.nlm.nih.gov/34781363/ （開啟新視窗）

Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. （開啟新視窗）

Leahy MF, Trentino KM, May C, Swain SG, Chuah H, Farmer SL.

來源‎: Transfusion 2017;57(9):2189-96.

檢索‎: PubMed 28671296

DOI碼‎: 10.1111/trf.14191

https://www.ncbi.nlm.nih.gov/pubmed/28671296 （開啟新視窗）

Impact of a conservative red blood cell transfusion strategy in children undergoing hematopoietic stem cell transplantation. （開啟新視窗）

Lightdale JR, Randolph AG, Tran CM, Jiang H, Colon A, Houlahan K, Billet A, Sloan S, Lehmann LE.

來源‎: Biol Blood Marrow Transplant 2012;18(5):813-7.

檢索‎: PubMed 22080050

DOI碼‎: 10.1016/j.bbmt.2011.10.043

https://www.ncbi.nlm.nih.gov/pubmed/22080050 （開啟新視窗）

The cost of blood: a study of the total cost of red blood cell transfusion in patients with β-thalassemia using time-driven activity-based costing. （開啟新視窗）

McQuilten ZK, Higgins AM, Burns K, Chunilal S, Dunstan T, Haysom HE, Kaplan Z, Rushford K, Saxby K, Tahiri R, Waters N, Wood EM.

來源‎: Transfusion 2019;59(11):3386-95.

檢索‎: PubMed 31664712

DOI碼‎: 10.1111/trf.15558

https://www.ncbi.nlm.nih.gov/pubmed/31664712 （開啟新視窗）

Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. （開啟新視窗）

Mehra T, Seifert B, Bravo-Reiter S, Wanner G, Dutkowski P, Holubec T, Moos RM, Volbracht J, Manz MG, Spahn DR

來源‎: Transfusion 2015;55(12):2807-15.

檢索‎: PubMed 26264557

DOI碼‎: 10.1111/trf.13260

https://www.ncbi.nlm.nih.gov/pubmed/26264557 （開啟新視窗）

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. （開啟新視窗）

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

來源‎: Cancer 2013;119(1):107-14.

檢索‎: PubMed 22744794

DOI碼‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 （開啟新視窗）

Budget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece. （開啟新視窗）

Nikolaidi E, Hatzikou M, Geitona M.

來源‎: Cost Eff Resour Alloc 2013;11(1):16.

檢索‎: PubMed 23870502

DOI碼‎: 10.1186/1478-7547-11-16

https://www.ncbi.nlm.nih.gov/pubmed/23870502 （開啟新視窗）

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. （開啟新視窗）

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

來源‎: Support Care Cancer 2012;20(1):159-65.

檢索‎: PubMed 21359879

DOI碼‎: 10.1007/s00520-010-1083-7

https://www.ncbi.nlm.nih.gov/pubmed/21359879 （開啟新視窗）

Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada. （開啟新視窗）

Pettigrew M, Garces K, Deuson R, Kassis J, Laroche V

來源‎: J Med Econ 2013;16(2):318-26.

檢索‎: PubMed 23216012

DOI碼‎: 10.3111/13696998.2012.756400

https://www.ncbi.nlm.nih.gov/pubmed/23216012 （開啟新視窗）

Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study. （開啟新視窗）

Ravangard R, Mirzaei Z, Keshavarz K, Haghpanah S, Karimi M.

來源‎: Hematology 2018;23(7):417-22.

檢索‎: PubMed 29157136

DOI碼‎: 10.1080/10245332.2017.1404262

https://www.ncbi.nlm.nih.gov/pubmed/29157136 （開啟新視窗）

The burden of blood transfusion: a utilization and economic analysis--a pilot study in patients with chemotherapy-induced anemia (CIA). （開啟新視窗）

Reitan JF, Kudrik FJ, Fox K, van Breda A, Shreay S, Corey-Lisle PK.

來源‎: J Med Econ 2013;16(5):633-8.

檢索‎: PubMed 23425291

DOI碼‎: 10.3111/13696998.2013.778269

https://www.ncbi.nlm.nih.gov/pubmed/23425291 （開啟新視窗）

Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction. （開啟新視窗）

Sarode R, Refaai MA, Matevosyan K, Burner JD, Hampton S, Rutherford C.

來源‎: Transfusion 2010;50(2):487-92.

檢索‎: PubMed 19804569

DOI碼‎: 10.1111/j.1537-2995.2009.02413.x

https://www.ncbi.nlm.nih.gov/pubmed/19804569 （開啟新視窗）

Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. （開啟新視窗）

Stallworth JR, Jerrell JM, Tripathi A.

來源‎: Am J Hematol 2010;85(10):795-7.

檢索‎: PubMed 20645429

DOI碼‎: 10.1002/ajh.21772

https://www.ncbi.nlm.nih.gov/pubmed/20645429 （開啟新視窗）

Increased hospital costs associated with red blood cell transfusion. （開啟新視窗）

Trentino KM, Farmer SL, Swain SG, Burrows SA, Hofmann A, Ienco R, Pavey W, Daly FF, Van Niekerk A, Webb SA, Towler S, Leahy MF.

來源‎: Transfusion 2015;55(5):1082-9.

檢索‎: PubMed 25488623

DOI碼‎: 10.1111/trf.12958

https://www.ncbi.nlm.nih.gov/pubmed/25488623 （開啟新視窗）

無輸血醫療的成本效益

血液科

中文繁體（國語）

血液科

https://assetsnffrgf-a.akamaihd.net/assets/ct/d8f8c0370e/images/syn_placeholder_sqr.png

Early intravenous iron administration in the Emergency Department reduces red blood cell unit transfusion, hospitalisation, re-transfusion, length of stay and costs. （開啟新視窗）

Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. （開啟新視窗）

Restrictive blood transfusion practices are associated with improved patient outcomes. （開啟新視窗）

Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United Kingdom. （開啟新視窗）

Recombinant activated factor VII use in critically ill infants with active hemorrhage. （開啟新視窗）

Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. （開啟新視窗）